Press Releases

PROKERA® Slim Corneal Bandage Now Approved in Taiwan for Treatment of Ocular Wounds

Bio-Tissue

Provides Taiwan eye care professionals with a well-established product to support healing in corneal-involved dry eye, keratitis, recurrent corneal erosions, and other ocular surface diseases Miami, FL – August 5, 2020 — Bio-Tissue, Inc., a TissueTech, Inc. company and leader in the clinical application of human birth tissue products for ocular surface disease and disorders, […]

SAWC Spring Meeting Features Symposium on Promising Advancements in the Treatment of Complex Wounds

Amniox Medical

Virtual symposium showcases results from study follow-up in which 86.2% of patients achieved complete closure of Wagner Grade 3-4 Diabetic Foot Ulcers (DFUs) with TTAX01 Cryopreserved Umbilical Cord allograft. Miami, FL – July 27, 2020 – Amniox Medical, Inc. (Amniox), a TissueTech, Inc. company and pioneer in the clinical application of human birth tissue-based products, […]

Amniox Announces Initiation for First of Two Phase 3 Clinical Trials of Cryopreserved Umbilical Cord TTAX01 Allograft to Treat Complex Wagner Grade 3-4 Diabetic Foot Ulcers

Amniox Medical

Company’s first biologic license application (BLA) candidate TTAX01 to enter Investigational New Drug (IND) Phase 3 Trials for Diabetic Foot Ulcer (DFU) indication as first biologic product to seek FDA approval for complex Wagner Grade 3 and 4 DFUs Miami, FL – June 30, 2020 – Amniox Medical, Inc. (Amniox), a TissueTech, Inc. company and […]

One-year Follow-up Study Results Find Cryopreserved Umbilical Cord Allograft for Treatment of Wagner Grade 3-4 Diabetic Foot Ulcers to be Safe with Higher than Expected Rates of Healing

Amniox Medical

86.2% of patients achieved complete closure with use of TTAX01 in the follow-up study, up from 50% confirmed closure during the original 16-week trial. Miami, FL – June 1, 2020 – Amniox Medical, Inc. (Amniox), a TissueTech, Inc. company and pioneer in the clinical application of human birth tissue-based products, announced today the results from […]

Pilot Study Shows Adjunctive Use of Umbilical Cord Allograft May Improve Clinical and Functional Outcomes Following Arthroscopic Repair of Talar Osteochondral Defects

Amniox Medical

Cryopreserved umbilical cord allograft is a novel treatment option due to its unique properties promoting a regenerative wound healing environment   Miami, FL – May 18, 2020 – Amniox Medical, Inc. (Amniox), a TissueTech, Inc. company and pioneer in the clinical application of human birth tissue-based products, announced today the results from a prospective, single-center, […]

First Annual National Mechanical Dry Eye Day is May 19, 2020

Bio-Tissue

Inaugural day to bring awareness to Mechanical Dry Eye, one of the most overlooked and often misdiagnosed age-related eye conditions Miami, FL – May 4, 2020 – Bio-Tissue, Inc., a TissueTech, Inc. company and leader in the clinical application of human birth tissue products for ocular surface disease and disorders, has announced that the first-ever […]

TissueTech Announces Additional Professional Education Events for Physicians and Staff During April, May, and June

TissueTech

Live webinars focus on Ophthalmic, Wound Care, Podiatry, and Orthopedic Indications using Cryopreserved Human Birth Tissue Miami, Fla. – April 21, 2020 – TissueTech, Inc., the pioneer in the development and clinical application of regenerative human birth tissue products and parent company of Amniox Medical, Inc. and Bio-Tissue, Inc., announced today that they have rolled […]

TissueTech Receives Regenerative Medicine Advanced Therapy (RMAT) Designation from U.S. Food and Drug Administration

TissueTech

RMAT designation reinforces clinical significance of investigational biologic product TTAX02 used during in-utero fetal surgical repair of spina bifida Miami, Fla. – April 16, 2020 – TissueTech, Inc., the pioneer in the development and clinical application of regenerative human birth tissue products, announced today that the U.S. Food and Drug Administration (FDA) has granted their […]

Bio-Tissue Announces First Annual National Mechanical Dry Eye Day

Bio-Tissue

To bring awareness to Mechanical Dry Eye (MDE), one of the most overlooked and often misdiagnosed age-related eye conditions Miami, FL – April 10, 2020 – Bio-Tissue, Inc., a TissueTech, Inc. company and leader in the clinical application of cryopreserved amniotic membrane products for ocular surface disease and disorders, has announced the first-ever National Mechanical […]

Leading Experts in Ophthalmology Come Together to Establish New Standard of Care Consensus Guidelines for Using Cryopreserved Amniotic Membrane to Treat Corneal Diseases

Bio-Tissue

Bio-Tissue, Inc. (Bio-Tissue), a TissueTech, Inc. company and pioneer and market leader in the ocular surface clinical application of human birth tissue-based products, announced today the availability of a collaborative publication designed to help clinicians optimize outcomes by improving the management of cornea-involved ocular surface diseases and the preparation of the ocular surface for refractive cataract surgery, all of which present continued unmet needs.

Archives

  • 2020
  • 2019
  • 2018